|
Jun 25
|
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
|
|
Jun 20
|
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium
|
|
Sep 11
|
NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting
|
|
Sep 5
|
NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference
|